FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667023> ?p ?o ?g. }

• W4385667023 endingPage "e43614c0" @default.
• W4385667023 startingPage "e43614c0" @default.
• W4385667023 abstract "Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Daratumumab (Dara), given as monotherapy or in combination with other agents, and ixazomib (Ixa), combined with lenalidomide (len) and dexamethasone (dex), have shown antitumor activity with acceptable safety in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Aims: To present the final outcomes of the DARIA study assessing the efficacy/safety of the Dara-Ixa-dex combination as second-line therapy in pts with RRMM previously treated with a len-based regimen. Methods: DARIA, a prospective, open-label, multicenter, phase 2 study, included adult pts with RRMM after one prior line with a len-based regimen and a Karnofsky Performance Status (KPS) score ≥70. In the induction phase (nine 28-day cycles), pts received: Dara 16mg/kg (weekly for cycles 1–2, bi-weekly for cycles 3–6, and every 4 weeks [Q4W] thereafter) given IV until November 2020 and SC at a fixed dose of 1800 mg thereafter; oral Ixa 4mg (days 1, 8, 15 of each cycle); and oral dex 40mg (weekly, each cycle). In the maintenance phase, pts received Dara Q4W and Ixa on the same schedule until disease progression/unacceptable toxicity. The primary endpoint was overall response rate (ORR). Other endpoints included overall survival (OS), progression-free survival (PFS), safety, and the effects of the Dara-Ixa-dex combination on serum bone metabolism markers (C-terminal telopeptide of type 1 collagen [CTX], tartrate-resistant acid phosphatase isoform 5b [TRACP-5b], bone-specific alkaline phosphatase [bALP], and osteocalcin [OC]). PFS and OS were analyzed with the Kaplan–Meier method. Statistical significance was set at a=5%. Results: Fifty pts were included (median [range] age: 69 [50–89] years; male: 28 [56%]). At screening, 38 (76%) pts had a KPS score ≥90, and most were at stage ≤II by the International Staging System (ISS; 42, 84%) or by the revised ISS (47, 94%). Thirty-two (64%) pts were len-refractory and 17 (34%) had prior ASCT. At study completion, 13 (26%) pts were still on treatment and 37 (74%) pts had discontinued (disease progression, 29 [58%]; fatal serious adverse event [SAE], 3 [6%]; physician decision, 3 [6%]; adverse event [AE], 2 [4%];). The median (range) number of study treatment cycles was 9 (1–38). ORR was 64% (32 pts; complete response, 1 [2%] pt; very good partial response, 16 [32%] pts; partial response [PR], 15 [30%] pts). The median (range) time from first Dara-Ixa-dex dose until first response (≥PR) was 1 (1–18) months. At a median (range) follow-up of 22 (1–40) months, the median (95% confidence interval) OS and PFS were 29 (17–not reached) and 8 (5–16) months. The changes from baseline to 12 and 15 months for TRACP-5b and bALP were significant (p<0.05), as were those for OC at 3, 12 and 15 months (Table). Overall, 21 (42%) pts had ≥1 AE of grade ≥3. The most common grade 3-4 AE was thrombocytopenia (9 pts, 18%); four fatal SAEs were reported (pneumonia, infection, urinary tract infection, and lower respiratory tract infection). Fourteen (28%) pts had ≥1 SAE, the most common being acute kidney injury and pneumonia (2 pts [4.0%] each). Summary/Conclusion: Second-line treatment with Dara-Ixa-dex in pts with RRMM who were pretreated with a len-based regimen resulted in rapid (1 month) responses to ≥PR with an ORR of 64%. Less than half of the pts experienced grade ≥3 AEs. Overall, significant increases in CTX, TRACP-5b, bALP, and OC levels from baseline to 15 months were observed, with the respective trend being evident even from 3 months, suggesting an improvement in the osteolytic bone disease and a normalization of the bone remodeling process.Keywords: Multiple myeloma" @default.
• W4385667023 created "2023-08-09" @default.
• W4385667023 creator A5011812743 @default.
• W4385667023 creator A5012405296 @default.
• W4385667023 creator A5018522443 @default.
• W4385667023 creator A5020827486 @default.
• W4385667023 creator A5028178125 @default.
• W4385667023 creator A5038147464 @default.
• W4385667023 creator A5041125510 @default.
• W4385667023 creator A5041407463 @default.
• W4385667023 creator A5045531432 @default.
• W4385667023 creator A5048477374 @default.
• W4385667023 creator A5083511911 @default.
• W4385667023 creator A5087794120 @default.
• W4385667023 creator A5088691462 @default.
• W4385667023 date "2023-08-01" @default.
• W4385667023 modified "2023-10-18" @default.
• W4385667023 title "P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY" @default.
• W4385667023 doi "https://doi.org/10.1097/01.hs9.0000970508.43614.c0" @default.
• W4385667023 hasPublicationYear "2023" @default.
• W4385667023 type Work @default.
• W4385667023 citedByCount "0" @default.
• W4385667023 crossrefType "journal-article" @default.
• W4385667023 hasAuthorship W4385667023A5011812743 @default.
• W4385667023 hasAuthorship W4385667023A5012405296 @default.
• W4385667023 hasAuthorship W4385667023A5018522443 @default.
• W4385667023 hasAuthorship W4385667023A5020827486 @default.
• W4385667023 hasAuthorship W4385667023A5028178125 @default.
• W4385667023 hasAuthorship W4385667023A5038147464 @default.
• W4385667023 hasAuthorship W4385667023A5041125510 @default.
• W4385667023 hasAuthorship W4385667023A5041407463 @default.
• W4385667023 hasAuthorship W4385667023A5045531432 @default.
• W4385667023 hasAuthorship W4385667023A5048477374 @default.
• W4385667023 hasAuthorship W4385667023A5083511911 @default.
• W4385667023 hasAuthorship W4385667023A5087794120 @default.
• W4385667023 hasAuthorship W4385667023A5088691462 @default.
• W4385667023 hasBestOaLocation W43856670231 @default.
• W4385667023 hasConcept C126322002 @default.
• W4385667023 hasConcept C141071460 @default.
• W4385667023 hasConcept C143998085 @default.
• W4385667023 hasConcept C203092338 @default.
• W4385667023 hasConcept C2776063141 @default.
• W4385667023 hasConcept C2776364478 @default.
• W4385667023 hasConcept C2780108899 @default.
• W4385667023 hasConcept C2781098529 @default.
• W4385667023 hasConcept C2781119759 @default.
• W4385667023 hasConcept C2781413609 @default.
• W4385667023 hasConcept C29730261 @default.
• W4385667023 hasConcept C31760486 @default.
• W4385667023 hasConcept C535046627 @default.
• W4385667023 hasConcept C71924100 @default.
• W4385667023 hasConcept C90924648 @default.
• W4385667023 hasConceptScore W4385667023C126322002 @default.
• W4385667023 hasConceptScore W4385667023C141071460 @default.
• W4385667023 hasConceptScore W4385667023C143998085 @default.
• W4385667023 hasConceptScore W4385667023C203092338 @default.
• W4385667023 hasConceptScore W4385667023C2776063141 @default.
• W4385667023 hasConceptScore W4385667023C2776364478 @default.
• W4385667023 hasConceptScore W4385667023C2780108899 @default.
• W4385667023 hasConceptScore W4385667023C2781098529 @default.
• W4385667023 hasConceptScore W4385667023C2781119759 @default.
• W4385667023 hasConceptScore W4385667023C2781413609 @default.
• W4385667023 hasConceptScore W4385667023C29730261 @default.
• W4385667023 hasConceptScore W4385667023C31760486 @default.
• W4385667023 hasConceptScore W4385667023C535046627 @default.
• W4385667023 hasConceptScore W4385667023C71924100 @default.
• W4385667023 hasConceptScore W4385667023C90924648 @default.
• W4385667023 hasIssue "S3" @default.
• W4385667023 hasLocation W43856670231 @default.
• W4385667023 hasLocation W43856670232 @default.
• W4385667023 hasOpenAccess W4385667023 @default.
• W4385667023 hasPrimaryLocation W43856670231 @default.
• W4385667023 hasRelatedWork W2041302492 @default.
• W4385667023 hasRelatedWork W2478188943 @default.
• W4385667023 hasRelatedWork W2615497162 @default.
• W4385667023 hasRelatedWork W2920340622 @default.
• W4385667023 hasRelatedWork W2980429921 @default.
• W4385667023 hasRelatedWork W3089210822 @default.
• W4385667023 hasRelatedWork W3095535753 @default.
• W4385667023 hasRelatedWork W3114717300 @default.
• W4385667023 hasRelatedWork W4253966080 @default.
• W4385667023 hasRelatedWork W4366352960 @default.
• W4385667023 hasVolume "7" @default.
• W4385667023 isParatext "false" @default.
• W4385667023 isRetracted "false" @default.
• W4385667023 workType "article" @default.